Karyopharm Therapeutics | KPTI - Fremdkapital

Aktienkurs
6.66
Täglich Wechseln
-0.97 -12.71%
Monatlich
-33.86%
Jährlich
2.30%
Q1 Prognose
7.40




Fremdkapital Veränderung Datum
AbbVie USD 62.97B 12M 2025-09
Abbott USD 9.9B 1.7B 2025-12
Amgen USD 50B 2.43B 2025-12
AstraZeneca USD 26.14B 19.58B 2025-12
BioCryst Pharmaceuticals USD 428.67M 234.31M 2025-12
Bristol-Myers Squibb USD 42.85B 1.62B 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Enanta Pharmaceuticals USD 0 0 2024-12
GlaxoSmithKline GBP 14.71B 186M 2025-12
Incyte USD 30.2M 5.17M 2025-12
J&J USD 39.44B 30M 2025-12
Karyopharm Therapeutics USD -0.93 0.67 2024-12
MacroGenics USD 70M 256K 2025-12
Merck USD 39.97B 6B 2025-09
Nektar Therapeutics USD 107.51M 10.35M 2024-06
Novartis USD 29.59B 5.35B 2025-12
Novartis USD 29.59B 5.35B 2025-12
Pfizer USD 57.41B 93M 2025-09
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Roche Holding CHF 27.43B 966M 2025-12
Sangamo BioSciences USD 0 0 2022-06
Takeda JPY 4.27T 81.29B 2025-12
Tectonic Therapeutic USD 43K 57K 2025-12
TG Therapeutics USD 245.64M 305K 2025-12
Ultragenyx Pharmaceutical USD 763.74M 19.02M 2025-09
Xencor USD 76.48M 11.29M 2025-12